2nd TEST MGR

Duarte, CA US
April 2, 2020

The field of research regarding the gut microbiome and immuno-oncology is still relatively new and burgeoning. To date, there have been few large-scale prospective trials in this field and many studies are exploratory. Over the past few years, much attention has been focused on the gut microbiome and its impact on immuno-based cancer therapeutics. Although there exists evidence suggesting that modulating the gut microbiome may impact responses to immunotherapy, optimal strategies of how to achieve this are unclear and examined in an exploratory fashion. 

Target Audience

Physicians, nurses, and all other health care providers interested in the topic.

Learning Objectives

  • Demonstrate an understanding of the evidence and mechanisms behind the gut microbiome's potential to modulate cancer patients' responses to immunotherapy.
  • Discuss results of human studies to-date that have shown a critical role of the gut microbiome in impacting survival and tumor responses to immunotherapy. 
  • Outline ongoing trials of the gut microbiome and immuno-oncology at City of Hope.
  • Integrate gut microbiome studies in future projects.  
Activity summary
Available credit: 
  • 1.00 ABS MOC
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2nd TEST MGR for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
04/02/2020
Activity expires: 
04/03/2020
Event starts: 
04/02/2020 - 11:15pm PDT
Event ends: 
04/02/2020 - 11:45pm PDT
Add to calendar: 
Duarte
1500 E. Duarte Rd
Duarte, CA 91010
United States

Conference Room B

Sarah K. Highlander, PhD   Research Professor; Director, Clinical Microbiome Services Center; The Translational Research Institute

Dr. Highlander has indicated that she is a Consultant for the University of Southern California. Dr. Highlander will be discussing the off-label or investigational use of Paricalcitol.

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.


 

Available Credit

  • 1.00 ABS MOC
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2nd TEST MGR for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.